domeet webmaster

Shanghai Lanwei Medical Technology is mainly positioned as a platform company based on transdermal delivery of microneedles. Its main business is the independent development of soluble microneedles and non-soluble microneedles, and CRO / CDMO cooperative research and development.

Since the completion of the Series A financing led by Mingfeng Capital in the second half of last year, the company has successively completed the mass production R & D of high-density / ultra-high-density microneedle molds, established a 10,000-level cell and derivative product preparation workshop, and established a workshop in Jiangxi With the support of the government of Zhanggong District, Ganzhou City, the company set up a subsidiary company for soluble microneedles for medical and aesthetic purposes.

At the same time, in cooperation with the core expert in the field of metabolic diseases, a strong professor of Columbia University and Professor Liu Yi of Fudan University, based on a series of patented drugs in the field of metabolism, he participated in the formation of Aponia Medical Technology Co., Ltd., engaged in Research and development of metabolic microneedle drugs such as weight loss and adjuvant diabetes treatment.

At present, a certain type of vaccine cooperated with Shanghai Jiaotong University and other units has completed the preliminary evaluation. It has shown the same immune effect as the traditional vaccine injection method in the equivalent test, and it is planned to start expanding to other vaccines in 2020.

Now it has established cooperative relationships with more than ten professional medical beauty channels such as Silgen KSG. Soluble microneedle products for medical beauty will be officially launched in 2020, and it will cover mainstream medical beauty applications such as freckle and acne. .

In view of the huge application prospects of micro-needle technology, in order to accelerate the industrialization of micro-needle technology, the company has started the Series B financing and has made extensive and in-depth contacts with excellent industry funds such as semiconductors and medical care. It is estimated that 2020 The B round of financing was completed in the first half of the year.

Q1. In 2019, the company’s technology research and development (clinical trials or listing of drugs,What progress has been made in product, market, commercialization, financing, team, etc.?

In 2019, we mainly completed the mass production of high-density / ultra-high-density microneedle molds, the construction of a 10,000-level cell and derivative preparation workshop in Shanghai, and the establishment of the Jiangxi Ganzhou Medical Microneedle Soluble Microneedle Subsidiary and Ningbo Ningbo Metabolism Microneedle-like Drug Company.

Up to now, a total of 5 patents have been applied for, and a type of vaccine cooperated with Shanghai Jiaotong University and other units has completed the preliminary evaluation. It has shown the same immune effect as the traditional vaccine injection method in equivalent tests, and is planned for 2020. Began to expand to other vaccines in 2015.

The medical micro-aesthetic soluble microneedle series products cooperated with more than ten professional medical aesthetic channels such as Silgen will be officially launched in 2020, which will cover mainstream medical beauty applications such as freckle and acne.

Q2. In 2019, in the industry, the three things that have the biggest impact on your industry?

1. Mark R Prausnitz of Georgia Institute of Technology has developed a one-month long-acting contraceptive microneedle sticker, which means that microneedle administration can cover all administrations from immediate release to long-acting controlled release. demand.

2. The current international situation makes it possible that micro-needles based on MEMS technology will encounter unforeseen obstacles in China’s subsequent R & D and industrialization.

3. 3D additive technology has begun to emerge in the design and preparation of microneedles. Although the current cost of preparation is relatively high, it is expected to achieve breakthroughs in the application of low density hollow microneedles first.

Q3. In 2020, what new developments may the company make in terms of technology research and development, products, markets, commercialization, financing, and teams?

First, in 2020, there will be important progress in the B round of financing or capitalization, the team size will be greatly expanded, and the mass production scale of soluble microneedles will have a significant breakthrough.

Secondly, in the field of microneedle drugs, an important microneedle drug with a large market coverage will be developed.

Q4, 2020, according to the new progress mentioned before, will the company have some milestones? Why do you think this is important, and if it is realized, what impact will it have on companies and industries? How much and / or how much money and resources have been spent to achieve such a milestone? Why would this matter be more expensive and costly?

The mass production plan in 2020 will reach tens of millions of microneedles per year, and preclinical testing of a certain microneedle drug is completed. The increase in mass production will significantly increase the company’s sales performance and reduce production costs.

In addition, the research and development of microneedle drugs involves clinical testing, and the total investment scale is expected to reach 30-40 million.

Q5. In 2020, what are the most likely events, trends, and competition patterns that will occur in the industry and segmentation direction of the company? What is the most important competitiveness of the industry in the future? Where is the competitiveness of the company?

The high probability of microneedle technology will first be widely promoted and applied in the medical aesthetics industry, and it will become a hot spot in the medical aesthetics market in 2020. After the market cultivation in 2020, head companies such as Lanwei Medical Technology Co., Ltd., Zhongke Micro Needles, Natong and other leading medical and aesthetic channels may form applications, forming strong competition with Japanese and South Korean products already listed Competition, but there are also some low-tech medical beauty companies to launch low-quality low-cost micro-needle products disrupt the C-end market. The future competitiveness of the industry is mainly reflected in the scale of mass production and effective load. Lanwei currently has advantages in these two points.

Q6, 2020, on the track where the company is located, is there anything that must be done or a market for competition, if you miss it, you may fall behind or get out?

It is mainly two things, large-scale mass production and deep cultivation of the medical beauty market. If you miss it, it will be difficult to catch up in the future.

Q7. According to the company’s progress and competitiveness, what is the company’s long-term plan? Such as future layout, whether to expand to other segments, whether to target the secondary market, etc.

The company’s long-term plan is to be a platform-type company based on microneedle transdermal drug delivery. It cooperates with dominant APIs and proprietary drug companies to focus on the urgent need to solve the pain points of conventional drug delivery and has extensive needs. Drug. There will be secondary market considerations when the company develops to a certain stage.

For companies on the medical and health track, the New Technology Entrepreneurship Series has launched a “Review 2019, Looking Forward to 2020” event.

If you are interested in this series, welcome to participate in our “New Technology Entrepreneurship 2019” series of surveys. Download the survey questionnaire: https: //shimo.im / docs / qctChycdx6KRjy68, a questionnaire specific to innovative drugs: https://shimo.im/docs/rdJQQvCxvQgxRkvR, please send a response to caishuning@36kr.com